American Academy of Child and Adolescent Psychiatry: Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry, 48:961–973, 2009.
2.
CookeM, IrbyDM, SullivanW, LudmererKM: American medical education 100 years after the Flexner report. N Engl J Med, 355:1339–1344, 2006.
3.
FindlingRL, JohnsonJL, McClellanJ, FrazierJA, VitielloB, HamerRM, LiebermanJA, RitzL, McNamaraNK, LinglerJ, HlastalaS, PiersonL, PugliaM, MaloneyAE, KaufmanEM, NoyesN, SikichL: Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49:583–594, 2010.
4.
FlexnerA: Medical education in the United States and Canada: A report to the Carnegie Foundation for the Advancement of Teaching. New York: Carnegie Foundation for the Advancement of Teaching, 1910.
5.
InselTR, GogtayN: National Institute of Mental Health clinical trials: New opportunities, new expectations. JAMA Psychiatry, 71:745–746, 2014.
6.
LiebermanJA, StroupTS, McEvoyJP, SwartzMS, RosenheckRA, PerkinsDO, KeefeRS, DavisSM, DavisCE, LebowitzBD, SevereJ, HsiaoJK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353:1209–1223, 2005.
7.
McCabeSE, WestBT: Medical and nonmedical use of prescription stimulants: Results from a national multicohort study. J Am Acad Child Adolesc Psychiatry, 52:1272–1280, 2013.
8.
McClellanJ, KingMC: Genetic heterogeneity in human disease. Cell, 141:210–217, 2010.
9.
MolinaBS, HinshawSP, SwansonJM, ArnoldLE, VitielloB, JensenPS, EpsteinJN, HozaB, HechtmanL, AbikoffHB, ElliottGR, GreenhillLL, NewcornJH, WellsKC, WigalT, GibbonsRD, HurK, Houck PR; MTA CooperativeGroup: The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry, 48:484–500, 2009.
10.
RapoportJL, Inoff-GermainG: Responses to methylphenidate in attention deficit/hyperactivity disorder and normal children: Update 2002. J Atten Disord, 6Suppl 1:S57–S60, 2002.
11.
SantoshPJ, BellL, FioriF, SinghJ: Pediatric antipsychotic use and outcomes monitoring. J Child Adolesc Psychopharmacol, 27:546–554, 2017.
12.
WhitefordHA, DegenhardtL, RehmJ, BaxterAJ, FerrariAJ, ErskineHE, CharlsonFJ, NormanRE, FlaxmanAD, JohnsN, BursteinR, MurrayCJ, VosT: Global burden of disease attributable to mental and substance use disorders: Findings from the global burden of disease study 2010. Lancet, 382:1575–1586, 2013.
